P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

September 2014

Features

Health Care & Law

Legal Risk Management Opportunities, Pharmacy Practice, and P&T Committees

Part 2: Risk Management Recommendations

A malpractice claims analysis by an insurer, Healthcare Providers Service Organization, provides recommendations for avoiding errors and injuries. Case examples relate these suggestions to situations that are common in health care settings.
James O’Donnell, PharmD; and F. Randy Vogenberg, RPh, PhD

Hospitals Struggle With ACA Challenges

More Regulatory Changes Are in the Offing in 2015

Provisions in the Patient Protection and Affordable Care Act aim to reduce hospital admissions — and, by extension, hospital revenue. In some cases, the emphasis on bundled payments and other initiatives is speeding consolidations and closures.
Stephen Barlas

Drug–Gene Interactions: Inherent Variability in Drug Maintenance Dose Requirements

The influence of genetics on pharmacokinetics can introduce variability among individual patients that may cause treatment failure, toxicity, or both. Such variability, specifically in clearance rates, can influence drug maintenance dosing regimens.
Paul Westervelt; Kihoon Cho; David R. Bright, PharmD; and David F. Kisor, PharmD

Schizophrenia: Overview and Treatment Options

Schizophrenia is a complex disorder characterized by an array of symptoms. This heterogeneity has resulted in a lack of consensus regarding diagnostic criteria, etiology, and pathophysiology, and has complicated efforts to devise effective treatments.
Krishna R. Patel, PharmD, RPh; Jessica Cherian, PharmD, RPh; Kunj Gohil, PharmD, RPh; and Dylan Atkinson

Pipeline Plus

Schizophrenia Therapy Options Increasing

New medications may soon offer more effective treatments for the approximately 2.5 million patients globally with schizophrenia. Current therapies in 2012 yielded $5.2 billion in global market sales, but by 2022 that is expected to reach $7.9 billion.
Kunj Gohil, PharmD, RPh; and Brielle Carramusa

Departments

Medication Errors

Too Many Abandon the “Second Victims” of Medical Errors

Matthew Grissinger, RPh, FaScP

Prescription: Washington

New Controversy for 340B: OPA Rebuffs Ruling by Court

stephen Barlas

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Pharmaceutical Approval Update

Belinostat (Beleodaq) for peripheral T-cell lymphoma; C1-esterase inhibitor (Ruconest) for acute attacks in hereditary angioedema; and tedizolid phosphate (Sivextro) for acute bacterial skin and skin structure infections
Marvin M. Goldenberg, PhD, RPh, MS

Drug Forecast

Loxapine Inhalation Powder (Adasuve)

A New and Innovative Formulation of an Antipsychotic Treatment for Agitation

Jose Valdes, PharmD; Travis Shipley; and Jose A. Rey, MS, PharmD, BCPP